PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsErgotamine
Ergotamine
Caffeine / Ergotamine, Ergomar, Migergot (ergotamine) is a small molecule pharmaceutical. Ergotamine was first approved as Cafergot on 1982-01-01. It is used to treat cluster headache and migraine disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 1D. In addition, it is known to target 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Caffeine
+
Ergotamine tartrate
Tradename
Company
Number
Date
Products
CAFERGOTNovartisN-006620 DISCN1982-01-01
1 products
CAFERGOTNovartisN-009000 DISCN1982-01-01
1 products, RLD
Hide discontinued
Ergotamine tartrate
Tradename
Company
Number
Date
Products
MEDIHALER ERGOTAMINE3MN-012102 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ergomarANDA2022-10-25
ergotamineANDA2013-04-10
ergotamine tartrate and caffeineANDA2021-12-21
ergotamine tartrate, caffeineANDA2022-02-10
migergotANDA2022-11-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cluster headacheHP_0012199D003027G44.00
migraine disordersEFO_0003821D008881G43
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N02: Analgesics
— N02C: Antimigraine preparations
— N02CA: Ergot alkaloids, antimigraine
— N02CA02: Ergotamine
— N02CA52: Ergotamine, combinations excl. psycholeptics
— N02CA72: Ergotamine, combinations with psycholeptics
HCPCS
Code
Description
J1110
Injection, dihydroergotamine mesylate, per 1 mg
Clinical
Clinical Trials
9 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G431—31—5
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine without auraD020326EFO_0005296G43.01—3——4
Migraine with auraD020325EFO_0005295G43.11—3——4
Tension-type headacheD018781HP_0012228G44.2——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pure autonomic failureD054970——1————1
Orthostatic hypotensionD007024—I95.11————1
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FibrosisD005355——————11
Parkinson diseaseD010300EFO_0002508G20————11
Heart valve diseasesD006349EFO_0009551I08————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameErgotamine
INNergotamine
Description
Ergotamine is a peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10. It has a role as a non-narcotic analgesic, a vasoconstrictor agent, a serotonergic agonist, an alpha-adrenergic agonist, a mycotoxin and an oxytocic. It is a conjugate base of an ergotamine(1+).
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
Identifiers
PDB—
CAS-ID113-15-5
RxCUI—
ChEMBL IDCHEMBL442
ChEBI ID64318
PubChem CID8223
DrugBankDB00696
UNII IDPR834Q503T (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Migergot – Horizon Therapeutics Public
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Ergotamine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,973 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ergomar, Ergotamine, Ergotamine tartrate and caffeine, Ergotamine tartrate, caffeine, Migergot
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
758 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use